Gastric signet ring cell carcinoma (GSRCC) is a distinct subtype of gastric cancer (GC) with unique epidemiological and pathogenic characteristics. Despite its clinical significance, large-scale ...
(A) Unsupervised clustering of 112 GSRCC cases identified key proteins with significant differences between tumors and NATs, focusing on the top 100 proteins with a FC > 1.5 and P value < 0.05. (B) ...
Concordance of PD-L1 combined positive score (CPS) analysis between primary gastric cancer and matched peritoneal metastasis.
Gastric cancer research continues to be a dynamic field, encompassing a diverse spectrum of investigations from early diagnosis to molecular profiling and novel therapeutic strategies. As one of the ...
Use of PPV of [18F]FAPI-74 PET to identify FAP expression in gastrointestinal cancers: Results from a prospective multicenter phase 2 study. Diagnostic statistics for metastasis for 18F-FDG and ...
BOSTON--(BUSINESS WIRE)--Signet Therapeutics, a biotech company using organoid disease models and AI to advance targeted cancer therapy, today announced that the FDA has granted its IND application ...
Signet Therapeutics Inc. has received IND clearance from the FDA for SIGX-1094 as a potential treatment for diffuse gastric cancer. A phase I trial is planned in patients with diffuse gastric cancer ...
Reviewed by Anuj K. Patel, MD, Clinical Director of the Center for Esophageal and Gastric Cancer at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results